These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32685913)

  • 21. Adverse events associated with Measles and Rubella vaccination campaign 2019 in India.
    Sharma R; Gaur A
    Clin Exp Vaccine Res; 2021 Jan; 10(1):44-46. PubMed ID: 33628753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse Event Following Immunization (AEFI) in Children: An Analysis of Reporting in VigiAccess.
    Pandey D; Mehta G; Sachdeva M; Tripathi R
    Drug Res (Stuttg); 2022 Oct; 72(8):435-440. PubMed ID: 35724674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing safety of Ontario's publicly funded MMR and MMRV immunization programs, 2012 to 2016.
    Seo CY; Rashid M; Harris T; Stapleton J; Deeks SL
    Paediatr Child Health; 2020 Oct; 25(6):358-364. PubMed ID: 32963648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India.
    Basavaraja CK; Sebastian J; Ravi MD; John SB
    Ther Adv Vaccines Immunother; 2021; 9():25151355211055833. PubMed ID: 34841193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of adverse events following pentavalent and diphtheria-tetanus-pertussis vaccines among Nigerian children.
    Sadoh AE; Nwaneri DU; Ogboghodo BC; Sadoh WE
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):119-122. PubMed ID: 28585776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India.
    Chakraborty A; Reval N; Kamath L
    Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios.
    Ankrah DNA; Darko DM; Sabblah G; Mantel-Teeuwisse A; Leufkens HMG
    Hum Vaccin Immunother; 2018 Jan; 14(1):172-178. PubMed ID: 29172941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revaccination and Adverse Event Recurrence in Patients with Adverse Events following Immunization.
    Muñoz CE; MacDonald B; Pham-Huy A; Vaudry W; Pernica JM; Boucher FD; Constantinescu C; Sadarangani M; Bettinger JA; Tapiéro B; Morris SK; McConnell A; Cowan J; Zafack J; Upton J; Abdurrahman Z; McHenry M; Hildebrand KJ; Noya F; De Serres G; Halperin SA; Top KA;
    J Pediatr; 2022 Nov; 250():45-53.e3. PubMed ID: 35948192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of Monkeypox Vaccine Using Active Surveillance, Two-Center Observational Study in Italy.
    Montalti M; Di Valerio Z; Angelini R; Bovolenta E; Castellazzi F; Cleva M; Pandolfi P; Reali C; Resi D; Todeschini R; Gori D
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
    Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
    JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono AB; Nébié I; Konaté AT; Berges GD; Diarra A; Ouedraogo M; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jan; 102():517-523. PubMed ID: 33176205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign.
    D'Souza RM; Campbell-Lloyd S; Isaacs D; Gold M; Burgess M; Turnbull F; O'Brien E
    Commun Dis Intell; 2000 Feb; 24(2):27-33. PubMed ID: 10758692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse Events Following Immunization- The Known Unknowns and Black Box : Based on 10th Dr. I. C. Verma Excellence Award for Young Pediatricians Delivered as Oration on 9th Oct. 2022.
    Das MK
    Indian J Pediatr; 2023 Aug; 90(8):817-825. PubMed ID: 37233889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of seizures after measles-mumps-rubella immunization.
    Griffin MR; Ray WA; Mortimer EA; Fenichel GM; Schaffner W
    Pediatrics; 1991 Nov; 88(5):881-5. PubMed ID: 1945626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.